Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
114 hedge funds and large institutions have $564M invested in Revance Therapeutics, Inc. in 2019 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 43 increasing their positions, 25 reducing their positions, and 17 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 25
24% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 17
2% more funds holding
Funds holding: 112 → 114 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
14% less capital invested
Capital invested by funds: $656M → $564M (-$92.4M)
49% less call options, than puts
Call options by funds: $740K | Put options by funds: $1.46M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$11.4M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$9.65M |
| 3 |
Renaissance Technologies
New York
|
+$5.41M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.01M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$17.9M |
| 2 |
Morgan Stanley
New York
|
-$1.29M |
| 3 |
Two Sigma Investments
New York
|
-$1.02M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$796K |
| 5 |
Goldman Sachs
New York
|
-$741K |
RVNC Hedge Fund Activity: Q2 2019 in Review
114 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2019, worth a combined $564M — down 14% from $656M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new RVNC positions and 17 closed out — a net gain of 4 holders — while 43 added to existing stakes and 25 trimmed.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $11.4M. The largest seller was JP Morgan Chase, cutting an estimated $17.9M.
- 114 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2019, up from 112 in Q1 2019.
- Funds reported $564M of Revance Therapeutics, Inc. stock for Q2 2019, down 14% quarter-over-quarter.
- 21 funds opened new Revance Therapeutics, Inc. positions in Q2 2019 and 17 closed out, a net change of +4 holders.
- The largest Revance Therapeutics, Inc. buyer in Q2 2019 was ArrowMark Colorado Holdings, an estimated $11.4M added.
- The largest Revance Therapeutics, Inc. seller in Q2 2019 was JP Morgan Chase, an estimated $17.9M sold.
Based on aggregated 13F filings for Q2 2019.